Overview

Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:
0

Participant gender:
All

Summary

Given that 5-HT3 receptors are indirect inhibitors of cortico-mesolimbic DA release, the 5-HT3 receptor antagonist ondansetron augmentation might potentially have efficacy in the treatment of resistant Obsessive Comulsive Disorder (OCD) patients on combined SRIs and antipsychotics.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Institute of Neuroscience, Florence, Italy

Treatments:

Ondansetron

Criteria

Inclusion Criteria:

1. adults aged 18 to 55

2. a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of ≥ 20 after ≥ 12 weeks of
treatment with an established effective dose of an Selective Serotonin Reuptake
Inhibitors or clomipramine and after ≥ 10 weeks of augmentation treatment with
antipsychotics (risperidone at least 2 mg/day quetiapine at least 150 mg/day;
olanzapine at least 5mg/day; haloperidol titrated at least 10 mg/day; aripiprazole at
least 10 mg/day)

Exclusion Criteria:

1. a history of alcohol or substance abuse

2. current severe depressive symptoms, bipolar disorder, panic disorder, schizophrenia,
or other psychiatric conditions

3. heart disease, arrhythmia, liver problems, including cirrhosis, seizures, glaucoma or
serious medical disease

4. hoarding as only Obsessive Compulsive symptom

5. women of childbearing potential not using a medically acceptable contraceptive method.